Literature DB >> 11221863

Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability.

V L Whitehall1, M D Walsh, J Young, B A Leggett, J R Jass.   

Abstract

The significance of low-level DNA microsatellite instability (MSI-L) is not well understood. K-ras mutation is associated with MSI-L colorectal cancer and with the silencing of the DNA repair gene O-6-methylguanine DNA methyltransferase (MGMT) by methylation of its promoter region. MGMT methylation was studied in sporadic colorectal cancers stratified as DNA microsatellite instability-high (n = 23), MSI-L (n = 44), and microsatellite-stable (n = 23). Methylation-specific PCR was used to detect MGMT-promoter hypermethylation in 3 of 23 (13%) microsatellite instability-high, in 28 of 44 (64%) MSI-L, and in 6 of 23 (26%) microsatellite-stable cancers (P = 0.0001). K-ras was mutated in 20 of 29 (69%) methylated MSI-L cancers and in 2 of 15 (13%) unmethylated MSI-L cancers (P = 0.001), indicating a relationship between MGMT-methylation and mutation of K-ras. Loss of nuclear expression of MGMT was demonstrated immunohistochemically in 23 of 31 (74%) cancers with methylated MGMT and in 10 of 49 (20%) cancers with nonmethylated MGMT (P < 0.0001). Loss of expression of MGMT was also demonstrated in 9 of 31 serrated polyps. Silencing of MGMT may predispose to mutation by overwhelming the DNA mismatch repair system and occurs with greatest frequency in MSI-L colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221863

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  70 in total

1.  Left and right sided large bowel cancer.

Authors:  Susan Richman; Julian Adlard
Journal:  BMJ       Date:  2002-04-20

Review 2.  Serrated adenoma of the colorectum: a lesion with teeth.

Authors:  Jeremy R Jass
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.

Authors:  Tamara L Znajda; Shinichi Hayashi; Peter J Horton; John B Martinie; Prosanto Chaudhury; Victoria A Marcus; Jeremy R Jass; Peter Metrakos
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

4.  Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.

Authors:  Edward J Fox; Dermot T Leahy; Robert Geraghty; Hugh E Mulcahy; David Fennelly; John M Hyland; Diarmuid P O'Donoghue; Kieran Sheahan
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

5.  CIMP and colon cancer gets more complicated.

Authors:  William M Grady
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

Review 6.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 7.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 8.  Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.

Authors:  Oscar Murcia; Miriam Juárez; Eva Hernández-Illán; Cecilia Egoavil; Mar Giner-Calabuig; María Rodríguez-Soler; Rodrigo Jover
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

Review 9.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

10.  Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients.

Authors:  Yang Liu; Qing Lan; Jill M Siegfried; James D Luketich; Phouthone Keohavong
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.